Show simple item record

dc.contributor.authorEvans, D Gareth R
dc.contributor.authorHowell, Anthony
dc.date.accessioned2009-08-27T08:27:16Z
dc.date.available2009-08-27T08:27:16Z
dc.date.issued2004
dc.identifier.citationAre BRCA1- and BRCA2-related breast cancers associated with increased mortality? 2004, 6 (1):E7 Breast Cancer Res.en
dc.identifier.issn1465-542X
dc.identifier.pmid14680492
dc.identifier.doi10.1186/bcr748
dc.identifier.urihttp://hdl.handle.net/10541/78796
dc.description.abstractThere has been contradictory evidence as to whether BRCA1 associated breast cancers have a poorer prognosis than non-BRCA1 cancers. In this issue of Breast Cancer Research Robson and colleagues provide further evidence for poorer survival in BRCA1 carriers and show that it could be attributed to failure to treat small node-negative grade 3 breast cancers with chemotherapy. There still remains little evidence for a survival difference for BRCA2 related breast cancers. Although the high contralateral breast cancer risk is confirmed by this study there is no real evidence for an increase in ipsilateral recurrence or new primary breast cancers in mutation carriers up to the 10-year point.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshBRCA1 Protein
dc.subject.meshBRCA2 Protein
dc.subject.meshBreast Neoplasms
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshGerm-Line Mutation
dc.subject.meshHumans
dc.subject.meshMultivariate Analysis
dc.subject.meshRisk Factors
dc.subject.meshSurvival Analysis
dc.subject.meshTime Factors
dc.titleAre BRCA1- and BRCA2-related breast cancers associated with increased mortality?en
dc.typeArticleen
dc.contributor.departmentAcademic Unit of Medical Genetics and Regional Genetics Service, St Mary's Hospital, Manchester, UK. Gareth.Evans@CMMC.nhs.uken
dc.identifier.journalBreast Cancer Researchen
html.description.abstractThere has been contradictory evidence as to whether BRCA1 associated breast cancers have a poorer prognosis than non-BRCA1 cancers. In this issue of Breast Cancer Research Robson and colleagues provide further evidence for poorer survival in BRCA1 carriers and show that it could be attributed to failure to treat small node-negative grade 3 breast cancers with chemotherapy. There still remains little evidence for a survival difference for BRCA2 related breast cancers. Although the high contralateral breast cancer risk is confirmed by this study there is no real evidence for an increase in ipsilateral recurrence or new primary breast cancers in mutation carriers up to the 10-year point.


This item appears in the following Collection(s)

Show simple item record